How Much Is Descovy Without Insurance in 2026? Full Cost Guide

What is Descovy?

Descovy is the brand name for emtricitabine/tenofovir alafenamide (FTC/TAF), manufactured by Gilead Sciences. FDA-approved for HIV PrEP in October 2019, it's a once-daily oral tablet. Descovy is generally tolerated better than older-generation Truvada, particularly regarding kidney and bone effects — though it may cause modest weight gain and increases in cholesterol in some people.

Important limitation: Descovy is not FDA-approved for people at risk of HIV through receptive vaginal sex. Clinical trial data supporting its effectiveness in this population is still being collected. For cisgender women and anyone at risk through vaginal sex, generic Truvada (TDF/FTC) remains the approved choice.

Descovy list price: the sticker shock number

Gilead's published Wholesale Acquisition Cost for a 30-day supply of Descovy is approximately $2,180. That annualizes to roughly $26,160 per year.

Descovy list price	Timeframe
~$2,180	Per 30-day supply
~$26,160	Per year
~$72	Per day (list price)

This number shocks people, and for good reason — it's more than most Americans spend on rent. But the list price is rarely what you pay. Between commercial insurance, copay savings cards, Medicaid, Medicare, and Gilead's Medication Assistance Program, the vast majority of Descovy users pay $0 out of pocket per month.

Descovy cost with commercial insurance

If you have private insurance through an employer or the ACA marketplace, Descovy is typically covered on your plan's formulary — but often in a higher pricing tier than generic PrEP. Your cost depends on your plan's structure:

• If you've met your deductible: You'll owe a copay (typically $30–$200/month) or coinsurance (typically 20–40% of the drug cost).
• If you haven't met your deductible: You may owe the full list price until the deductible is met.

Gilead Copay Savings Program: $7,200/year

Here's where it gets much better. Gilead's Copay Savings Program covers up to $7,200 per year in out-of-pocket costs for commercially insured patients on Descovy. There's no income restriction. For most commercially insured people, this means your monthly cost drops to $0.

Enroll at GileadAdvancingAccess.com or ask your prescriber or pharmacist to enroll you. The program excludes Medicare, Medicaid, Tricare, and VA coverage by federal law.

Descovy cost with Medicaid

All 50 state Medicaid programs cover Descovy, typically at $0 copay under the ACA preventive services mandate for PrEP. Some state Medicaid plans require prior authorization or step therapy (trying generic Truvada first), but coverage itself is universal.

Descovy cost with Medicare

Medicare Part D covers Descovy, but your cost depends on your specific plan and where you are in the Part D benefit structure. Medicare beneficiaries cannot use Gilead's commercial copay card (federal anti-kickback rules), but may qualify for:

• Good Days Foundation copay assistance (up to $7,500/year, income limit 500% FPL)
• Medicare Extra Help / Low-Income Subsidy (significantly reduces Part D costs for lower-income beneficiaries)
• State Pharmaceutical Assistance Programs (SPAPs) in some states

Descovy without insurance: how to get it free

If you're uninsured, Descovy has one of the best patient assistance programs in all of pharma. Gilead Advancing Access provides free Descovy to qualifying uninsured patients — and critically, it's one of the few major assistance programs that does not require a Social Security Number, making it accessible to undocumented residents.

Is Descovy worth the price over generic PrEP?

This is the honest question every PrEP user should think through. Here's the clinical reality:

	Generic TDF/FTC	Descovy (FTC/TAF)
Cash price	~$30/month	~$2,180/month
Efficacy	99%+ with adherence	99%+ with adherence
Approved populations	All at-risk adults	Not approved for receptive vaginal sex
Kidney effects	Small, reversible	Less than TDF
Bone density effects	Small, reversible	Less than TDF
Weight / lipids	Weight-neutral	Modest weight gain, lipid increases

Clinical guidelines generally consider both drugs first-line PrEP for their approved populations. If you have pre-existing kidney disease, osteoporosis, or risk factors for bone loss, Descovy may be clinically preferable. Otherwise, the decision is often about cost, tolerability, and insurance coverage. For someone paying cash without insurance or assistance, generic TDF/FTC is dramatically cheaper.

Frequently asked questions